Search
for
Sort by
Research 30 of 1000+
- Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
- Synthesis, Characterisation, andIn VitroAnticancer Activity of Curcumin Analogues Bearing Pyrazole/Pyrimidine Ring Targeting EGFR Tyrosine Kinase
- 078 The transmembrane protein LRIG1 regulates receptor tyrosine kinases in skin development and homeostasis
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
- Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
- MiR‐200c‐3p as a novel genetic marker and therapeutic tool for alopecia areata
- Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer
- An unusual terminal hair growth on the nose tip associated with gefitinib therapy
- Prevention of erlotinib-induced folliculitis with doxycycline
- Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Gefitinib-induced hair alterations: Figure 1
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- A Case of Cicatricial Alopecia Associated with Erlotinib
- An overview of management of drug-induced hair and nail disorders
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- A Case of Hair Change and Acneiform Eruption Induced by ZD1839 (Iressa$^{(R)}$)
- Non-small cell lung carcinoma spheroid models in agarose microwells for drug response studies
- Drug Repurposing Patent Applications April–June 2021
- Sorting Out the Seeming Increase in Lung Cancer in Women Who Have Never Smoked
- Synthesis, Anticancer and Molecular Docking Studies of 2-(4-chlorophenyl)-5-aryl-1,3,4-Oxadiazole Analogues